Primary: To identify potential diagnostic cytokine profiles for an allergic reaction towards a dental device in patients with symptoms of oral metal allergy. Which might lead to a better understanding of allergic based systemic reaction of oral…
ID
Source
Brief title
Condition
- Allergic conditions
- Skin and subcutaneous tissue disorders NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
* Determine differences in cytokine profiles obtained from gingiva crevicular
fluid samples derived from both test groups.
* Determine correlation of lymphocyte proliferation test/cytokine secretion
test upon in vitro stimulation with metal salts (Ni, Pd) with suspected metal
allergy.
* Determine correlation of skin tape strip secretome with suspected metal
allergy
Secondary outcome
n/a
Background summary
Skin and oral mucosa (e.g. gingiva, buccal mucosa, palatum) are both fully
immunologically competent tissues involved in the induction and effector phase
of the immune response. They both function by forming a barrier to harmful
environmental factors with the capacity to maintain homeostasis and regulate
immune responses when dealing with pathogens. However, clinical observations
suggest that these tissues react differently to insults arising from the
environment. For example, differences were observed in immune reactions to
nickel when comparing skin to oral mucosa. Whereas first nickel exposure via
the skin can result in sensitization, a first oral exposure to nickel e.g. in
the form of dental braces has been shown to induce specific tolerance1 where an
oral exposure to a person that became allergic to nickel by skin contact can
result in an oral and systemic allergic reaction. This would indicate that skin
is immune-stimulatory and oral mucosa is tolerogenic at first exposure and
suggests a differential role for residential cells (e.g. keratinocytes,
fibroblasts and DC) and their cross-talk with immune cells within skin and oral
tissue.
However many allergies within the oral cavity have also been reported e.g.
nickel and palladium allergy caused by dental restorative materials2,3. An
allergic reaction due to an oral exposure to allergens can also often result in
systemic reactions, e.g face or foot eczema. This raises the question whether
oral or another skin exposure is the cause of those symptoms.
Currently, measurements for diagnostic purposes are indirectly made by patch
testing the skin of patients suspected of an allergy towards their metal dental
devices. Recently a new method became available (Meso Scale) that opens the
possibility to analyze the extremely low concentrations of cytokines within the
crevicular fluid within the gingival pocket around de tooth or oral dental
device. This will give the opportunity to compare cytokine profiles of skin and
mucosal exudate in patients with (systemic) symptoms of oral metal allergy.
With this study we will evaluate the immunological reaction of oral mucosa
(gingiva) directly in contact with palladium or nickel based dental devices and
compare this to healthy mucosa not directly in contact with palladium or
nickel. Furthermore, we aim to compare the oral mucosa immunological reaction
with a *gold standard*, the skin patch test (routine diagnostic). This study
will identify potential diagnostic cytokine profiles which will provide leads
to identifying an oral allergic reaction. The knowledge obtained might in the
future lead to the development of a totally new diagnostic approach for the
determination of *oral allergy* with systemic symptoms.
Study objective
Primary: To identify potential diagnostic cytokine profiles for an allergic
reaction towards a dental device in patients with symptoms of oral metal
allergy. Which might lead to a better understanding of allergic based systemic
reaction of oral exposure to metals in sensitized patients.
Secondary: To compare the immunological reaction of mucosa in contact with
palladium or nickel based dental devices with the cytokine profile obtained
from tape stripping of the routine diagnostic skin patch test site. And to
re-evaluate the peripheral blood lymphocyte assay as a diagnostic assay for
metal allergy.
This study will eventually lead to the development of a new diagnostic approach
for the determination of *oral allergy* with systemic symptoms.
Study design
Multi- center observational cross-sectional study.
Study burden and risks
Participants could benefit from the additional advice they receive about their
allergy. They could gain more information about their allergy. Also, if
possible, safe implant material alternatives can be proposed. Both methods
(crevicular washes and sequential adhesive tape stripping) are very low risk
procedures. Tape stripping can cause minor discomfort on removal and moderate
erythema resulting from application and removal. The collection of blood by
venipuncture is a routine clinical procedure and does not contain any specific
risk.
Gustav Mahlerlaan 3004
Amsterdam 1081 HZ
NL
Gustav Mahlerlaan 3004
Amsterdam 1081 HZ
NL
Listed location countries
Age
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
* Patients suspected of having an allergic reaction to palladium or nickel in their dental restorative material and who are orally exposed to these metals by their dental devices and who are scheduled to receive a routine skin patch test at the outpatient clinic Dermato-allergology & occupational dermatology at the VU University Medical Centre for diagnosis of nickel and palladium allergy.
* Patients must be willing to undergo crevicular fluid collection, venipuncture and skin adhesive tape stripping
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
* Pregnancy or lactation
* Age under 18 or above 80
* Smoking, no more than ten cigarettes per day
* Legally incompetent adults
* Usage of systemic immunosuppressive drugs (e.g. prednison, acitretine, adalimumab, efalizumab, etanercept, methoxsaleen, cyclosporine, azathioprine, infliximab and methothrexate) and antibiotics at least 2 weeks prior to starting of the study NB: Medication that reasonably not intervenes with the study procedures (e.g. an antihistaminicum can be used during the study)
* Severe disorders within the last 6 month, e.g. cancer, acute cardiac- and circularity disorders, serious diabetics
* Participation in a study with pharmaceutical within a period of at least 4 weeks prior to this study
* Immunological disorders, e.g. HIV, infectious hepatitis,
* Alcohol and drug abuse
* Eating or drinking (except water) in the morning preceding the first appointment
* Brushing of the teeth ( toothpaste) the morning preceding the first appointment
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL58719.029.16 |